Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush

Eli Lilly and Novo Nordisk both dominated GLP-1 headlines in Q2 2026, but one company raised guidance while the other announced layoffs, pipeline writedowns, and a dramatic price cut. The split screen tells a story that goes beyond which drug sells more.